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The Surveillance Monitoring for ART Toxicities (SMARTT) cohort of the Pediatric HIV/AIDS 
Cohort Study includes over 3,500 HIV-exposed but uninfected infants and children at 22 
sites in the US, including Puerto Rico. The goal of the study is to determine the safety 
of in utero exposure to antiretrovirals (ARVs) and to estimate the incidence of adverse 
events. Domains being assessed include metabolic, growth and development, cardiac, 
neurological, neurodevelopmental (ND), behavior, language, and hearing. SMARTT
employs an innovative trigger-based design as an efficient means to identify and evaluate 
adverse events. Participants who met a predefined clinical or laboratory threshold (trig-
ger) undergo additional evaluations to define their case status. After adjusting for birth 
cohort and other factors, there was no significant increase in the likelihood of meeting 
overall case status (case in any domain) with exposure to combination ARVs (cARVs), 
any ARV class, or any specific ARV. However, several individual ARVs were significantly 
associated with case status in individual domains, including zidovudine for a metabolic 
case, first trimester stavudine for a language case, and didanosine plus stavudine for 
a ND case. We found an increased rate of preterm birth with first trimester exposure 
to protease inhibitor-based cARV. Although there was no overall increase in congenital 
anomalies with first trimester cARV, a significant increase was seen with exposure to 
atazanavir, ritonavir, and didanosine plus stavudine. Tenofovir exposure was associated 
with significantly lower mean whole-body bone mineral content in the newborn period 
and a lower length and head circumference at 1 year of age. With ND testing at 1 year 
of age, specific ARVs (atazanavir, ritonavir-boosted lopinavir, nelfinavir, and tenofovir)
were associated with lower performance, although all groups were within the normal 
range. No ARVs or classes were associated with lower performance between 5 and
13 years of age. Atazanavir and saquinavir exposure were associated with late language 
emergence at 1 year, but not at 2 years of age. The results of the SMARTT study are 
generally reassuring, with little evidence for serious adverse events resulting from in utero 
ARV exposure. However, several findings of concern warrant further evaluation, and new 
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Antiretroviral (ARV) therapy during pregnancy has dramati-
cally reduced the rate of mother-to-child transmission of HIV, 
which is currently 2% or less in the US (1). However, the number 
of HIV-infected pregnant women has not decreased, result-
ing in a large number of infants who are not HIV infected but 
who were exposed, in  utero, to ARVs. Toxicities from in  utero 
exposure to ARVs, including mitochondrial toxicity, remain 
a major concern (2). Nucleoside reverse transcriptase inhibi-
tors (NRTIs) induce mitochondrial dysfunction by inhibiting 
replication of mitochondrial gamma DNA polymerase, leading 
to mitochondrial DNA depletion, mutations, and dysfunction 
(3). Some studies have identified clinical symptoms, including 
lactic acidosis, cardiomyopathy, and neurological abnormalities, 
suggesting mitochondrial dysfunction, in a small proportion of 
exposed infants (4–6).
The Pediatric HIV/AIDS Cohort Study (PHACS) includes a 
network of 22 clinical sites in the US and Puerto Rico. It con-
ducts  three longitudinal cohort studies of children born to 
HIV-infected mothers: (1) the Surveillance Monitoring for ART 
Toxicities (SMARTT) study of HIV-exposed but uninfected 
(HEU) infants and children, (2) the adolescent master protocol 
(AMP) study of perinatally HIV-infected children and adoles-
cents, and (3) the AMP up protocol which follows AMP subjects 
into young adulthood once they reach 18 years of age. AMP and 
AMP up also include a comparison group of HEU. The objec-
tive of SMARTT is to determine the safety of in utero exposure 
to ARVs among HEU children and to estimate the incidence 
of adverse events. Domains being assessed include metabolic, 
growth and development, cardiac, neurological, neurodevelop-
mental (ND), behavior, language, and hearing. Study visits are 
conducted annually until 5 years of age and then every other year, 
with specified clinical and laboratory evaluations. In addition, we 
enrolled a comparison group of 239 HIV-unexposed and unin-
fected (HUU) children of similar sociodemographic background 
to that of the SMARTT subjects at 1, 3, 5, and 9  years of age. 
These participants had a single evaluation and were not followed 
longitudinally.
The SMARTT study opened to enrollment in 2007 at 22 sites 
and includes 2 cohorts of HIV-infected mothers and their HEU 
children. The Static cohort enrolled 1,240 children less than 
12 years of age at enrollment and closed to further enrollment in 
2009. Seventy-seven percent of participants remain on study with 
a median age of 11.0 years and a median duration of follow-up of 
7.3 years. The dynamic cohort remains open to enrollment. As of 
March 2016, it includes over 2,300 mother–infant pairs who were 
enrolled during gestation or within 72 h of birth. Approximately 
250 mother–infant pairs are enrolled each year. Eighty-five per-
cent of dynamic cohort participants remain on study with median 
age of 3.2 years and a median duration of follow-up of 3.7 years. 
Overall, 48% of the SMARTT participants are females, 66% 
Black, and 33% Hispanic. Retention has been excellent with 85% 
of static and 80% of dynamic participants remaining on study at 
6 years. For additional characteristics of the SMARTT cohort, see 
Williams et al. (7).
There are a number of strengths of SMARTT. A complete 
history of in utero ARV exposure (8), coupled with longitudinal 
assessments from birth in the dynamic cohort, allows for careful 
consideration of various windows of exposure and how they may 
affect specific outcomes. Trigger-based surveillance is an efficient 
means to identify adverse events (9). The study addresses an 
extended spectrum of outcomes including epigenetic changes, 
alterations in mitochondrial DNA and intermediary metabo-
lism, and bone density in infants. It includes novel measures 
of in  utero exposure to ARVs, alcohol, and recreational drugs 
using meconium and hair (10, 11). It allows for nested, more 
intensive substudies, such as those addressing maternal nutri-
tion and tenofovir exposure of the fetus. Untangling the effect 
of individual ARVs is challenging, since most infected women 
take multiple ARVs during pregnancy. Assembling a comparison 
group of HEU children who were not exposed to ARVs in utero is 
not feasible in the US. Thus, most analyses compare subgroups of 
participants who were exposed or not exposed to different ARVs 
or ARV classes, considering the trimester of exposure or duration 
of exposure.
TRiGGeR-BASeD DeSiGn TO iDenTiFY 
ADveRSe evenT
In SMARTT, we employ an innovative trigger-based design as 
an efficient means to identify and evaluate adverse events, to 
estimate adverse event rates, and to test for association with 
in  utero and perinatal ARV exposures (9). Participants who 
meet a predefined clinical or laboratory threshold or “trigger” 
undergo additional specified evaluations to determine if they 
meet a predefined adverse event “case” definition. Most cases 
are identified using a computerized algorithm, eliminating 
the need for individual reviews. A SMARTT Review panel, 
comprising clinicians, biostatisticians, and epidemiologists, 
oversees the identification of cases and does individual reviews 
of participants meeting a trigger based on abnormal laboratory 
values and neurologic diagnoses. The specific triggers evaluated 
are shown in Table S1 of Supplementary Material. The domains 
considered were selected because they are known or suspected to 
result from mitochondrial dysfunction or other ARV-associated 
toxicities.
Among 2,680 SMARTT participants enrolled on December 
31, 2012, 48% met a trigger and 25% met case status in one or 
more domains (7). After adjusting for birth cohort and other 
factors, there was no significant increase in the likelihood of 
meeting overall case status (case in any domain) with exposure 
to combination ARVs (cARV) or any ARV class (Figure 1). No 
single ARV was associated with an increased risk of overall case 
status on adjusted analysis, although several were significant in 
the unadjusted analysis. However, several ARVs were significantly 
associated with case status in individual domains. Maternal 
zidovudine use was associated with meeting the metabolic case 
definition [adjusted relative risk (aRR) 1.69, 95% CI 1.08, 2.64, 
p = 0.022]. First trimester stavudine was associated with meet-
ing the language case definition (aRR 2.06, 95% CI 1.04, 4.09, 
p =  0.038), and didanosine plus stavudine use was associated 
with meeting the ND case definition (aRR 12.4, 95% CI 5.29, 29.1, 
p = 0.001). A number of exposures were protective of meeting 
case status, including, for metabolic case status, cARV, protease 
FiGURe 1 | Association of overall adverse event case status with in utero antiretroviral (ARv) exposures. *Adjusted model includes Black race or Puerto 
Rican origin, low caregiver education (<high school), first trimester maternal tobacco use, and birth cohort (≥2010 vs. <2010). Abbreviations: RR, relative risk; 
HAART; cARV, combination antiretrovirals; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside or nucleotide reverse transcriptase inhibitor; PI, 
protease inhibitor. From Ref. (7), used with permission.
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inhibitors (PIs), emtricitabine, ritonavir-boosted lopinavir, and 
ritonavir, and for ND case status, cARV.
PReGnAnCY OUTCOMeS
Maternal PI-based cARV during pregnancy has been associ-
ated with an increased rate of prematurity and low birth weight 
(12–14). In an analysis of 1,864 singleton births in the dynamic 
cohort, 18.6% of infants were preterm (<37  weeks gestation) 
and 7.3% small for gestational age (weight <10 percentile for 
gestational age). Eighty-nine percent of the mothers took cARV 
during their pregnancy. We found an increased risk of preterm 
birth [odds ratio (OR) 1.55, 95% CI 1.16, 2.07] and spontaneous 
preterm birth (OR 1.59, 95% CI 1.10, 2.30) with first trimester 
exposure to PI-based cARV, but not with NNRTI-based cARV 
or ≥3 NNRTIs, compared to no first trimester ARV use (15) 
(Figure 2). cARV use later in pregnancy was not associated with 
an increased risk. No significant increase in the rate of small for 
gestational age infants was observed with any regimen.
We investigated the association of birth defects with first 
trimester ARV exposure among 2,580 infants in both the static 
and dynamic cohorts, which included a review of individual 
defects by the study team. The overall prevalence of birth defects 
was 6.78 per 100 live births (95% CI 5.85, 7.82), higher than the 
general population estimate of 2.67% of the Metropolitan Atlanta 
Congenital Defects Program (16). It is also higher than that 
reported by the International Antiretroviral Pregnancy Registry 
(2.9%) and the Women and Infants Transmission Study (3.56%) 
for first trimester ARV exposure (17). There was a significant 
increase in the prevalence of birth defects over the course of the 
study. Among all reported birth defects, the most common were 
musculoskeletal (29.8%) and cardiovascular (23.1%). In unad-
justed analysis, the occurrence of birth defects was significantly 
increased with first trimester cARV exposure (OR 1.44, 95% 
CI 1.05, 1.97) and first trimester PI exposure (OR 1.51, 95% CI 
1.10, 2.07). However, when adjusted for birth cohort, CD4 dur-
ing early pregnancy and prematurity, the risks remained similar 
(OR 1.35 and 1.39, respectively) but were no longer significant 
(Figure  2). Among individual ARVs or ARV combinations, 
first trimester exposure to the PIs atazanavir (OR 1.95, 95% CI 
1.24, 3.05) and ritonavir (as a boosting agent) (OR 1.56, 95% CI 
1.11, 2.20) and the combination of didanosine plus stavudine 
(OR 8.19, 95% CI 1.53, 43.4) were associated with a significantly 
FiGURe 2 | First trimester antiretroviral exposure and pregnancy and 
infant outcomes (15, 16). Abbreviations: cARV, combination antiretrovirals; 
PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; 
NRTI, nucleoside or nucleotide reverse transcriptase inhibitor.
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increased rate  of birth defects in adjusted analysis. Specific 
congenital defects that were significantly associated with specific 
ARV exposures include male genital (zidovudine and lamivu-
dine), musculoskeletal (atazanavir, ritonavir, and didanosine 
plus stavudine), cardiovascular (atazanavir and ritonavir), and 
skin (atazanavir).
LACTiC ACiDOSiS
An elevated blood lactate level is useful in screening for mito-
chondrial dysfunction. Because of the difficulty in obtaining an 
appropriate venous blood sample in children, we utilized the 
point-of-care (POC) Lactate Pro device to measure capillary 
blood lactate concentrations annually in SMARTT (18). Among 
1,934 participants at a mean age of 3.0 years, 3.4% had a POC 
lactate >3 mmol/L. The mean lactate level decreased as the chil-
dren aged. The prevalence of elevated lactate following in utero 
exposure did not differ by ARV class but was significantly higher 
in those exposed to emtricitabine, efavirenz, cocaine, or opiates. 
No clinical findings were associated with an elevated lactate, but 
further analyses are planned.
GROwTH
Reports of the effects of in  utero ARV exposures on growth 
of HEU children are limited and have not revealed consistent 
patterns (19–21). Rapid weight gain leading to obesity and 
associated metabolic problems is increasing among children 
in the US. SMARTT participants were smaller than US refer-
ence standards at birth, with a mean weight z-score of −0.56 
(SD 0.85) and length z-score of −0.16 (SD1.0) (22). Nineteen 
percent were small for gestational age. By 2 years of age, their 
mean weight had caught up with US norms and continued to 
increase with age.
Use of tenofovir has been associated with loss of bone mineral 
density in adults (23) and children (24) and concerns about bone 
growth in non-human primates (25). In utero tenofovir exposure 
and low maternal vitamin D are associated with decreased fetal 
bone accrual and possible future fracture risk (26–28). Currently, 
70% of the pregnant mothers in SMARTT are receiving tenofovir 
during their pregnancy. In order to define the effect of in utero 
tenofovir exposure on newborn bone mineral content, we 
performed dual-energy X-ray absorptiometry (DXA) scans at 
2–3  weeks of age on 74 tenofovir-exposed and 69 unexposed 
infants (27). While the mean weight and length of the two groups 
at birth were similar, we found a 12% lower mean whole-body 
bone mineral content in those exposed to tenofovir (56.0 vs. 
63.8 g, p = 0.002), which persisted when adjusted for maternal 
age, smoking, HIV disease status and infant gestational age, sex, 
race, and length (p = 0.013). We are currently planning to repeat 
the DXA scans among these children at an older age to see if this 
finding persists.
We compared the growth at birth and 1  year of age of 449 
infants exposed in utero to cARV with tenofovir to 1,156 exposed 
to cARV without tenofovir. At birth, their mean weight, length, 
and head circumference were below US norms but similar in 
the two groups (z-scores: −0.63 and −0.66, −0.25 and −0.16, 
and −0.66 and −0.65, respectively) (29). There was no increased 
risk of low birth weight or being small for gestational age with 
tenofovir exposure. However, at 1 year of age, those with in utero 
tenofovir exposure had a slightly lower mean length and head 
circumference [difference in adjusted mean z scores: −0.14 
(p = 0.04) and −0.25 (p = 0.02), respectively], but their weights 
were similar.
CARDiAC FUnCTiOn
Mitochondrial dysfunction frequently affects the heart, and 
subclinical changes in left ventricular structure and function 
have been reported in HEU children with in utero ARV exposure 
(30). Thus, we performed echocardiograms on 417 HEU and 
98 HUU children between 2 and 7 years of age (31). We found 
no significant difference in measures of myocardial structure or 
function between the two groups. Among the HEU participants, 
we observed subclinical differences in measures of left ventricular 
structure and function with first trimester exposure to cARV and 
to specific ARVs. The left ventricular stress-velocity index (myo-
cardial contractility) was significantly decreased with exposure to 
cARV, tenofovir, emtricitabine, and ritonavir-boosted lopinavir, 
whereas the left ventricular end-diastolic posterior wall thickness 
was significantly elevated among those exposed to cARV, zidovu-
dine, lamivudine, nevirapine, and atazanavir. These subclinical 
findings suggest injury to the myocardium and highlight the need 
for longitudinal cardiac follow-up to assess long-term cardiac 
risk. About half of the HEU children in SMARTT had elevated 
levels of at least one cardiac or inflammatory biomarker, suggest-
ing that chronic inflammation may contribute to these cardiac 
5Van Dyke et al. Safety of Antiretroviral Exposure
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finding and may help to identify HEU children who need further 
cardiac evaluation (32).
neUROCOGniTive AnD LAnGUAGe 
FUnCTiOninG
Findings of cognitive deficits and structural and functional 
changes in the brains of animals and humans with ARV exposure 
support the need for continued study of brain and neurocognitive 
development, as the brain is heavily dependent upon mitochon-
drial integrity and is rapidly developing during in  utero ARV 
exposure (33–37). HEU youth are at increased risk for poor ND 
outcomes and while specific ARVs or classes have not been clearly 
implicated, concerns persist (38–41). Language acquisition is 
essential for social, academic, and long-term employment.
We evaluated 374 HEU and 49 HUU children from a similar 
background between 9 and 15 months of age using the Bayley-III 
assessment (41). Eighty-four percent of the HEU group had been 
exposed to cARV in utero. There were no significant differences 
between HEU and HUU infants or between cARV-exposed and 
unexposed HEU children in any of the five Bayley-III domain 
scores. In four of the five domains, the cARV-exposed group had 
a higher (although not significantly) adjusted mean score than 
the cARV-unexposed group. A number of significant differences 
were seen in the HEU groups with exposure to specific ARVs. 
Atazanavir exposure was associated with significantly poorer 
language performance, ritonavir-boosted lopinavir was associ-
ated with lower adaptive behavior performance, nelfinavir was 
associated with lower cognitive performance, and tenofovir was 
associated with lower social–emotional performance. In contrast, 
lamivudine exposure was associated with significantly higher 
social–emotional performance and ritonavir-boosted lopinavir 
was associated higher language performance. However, for all of 
these comparisons, both groups had median scores within the 
normal range.
For participants between 5 and 13  years of age, assess-
ments included the Wechsler Preschool and Primary Scale of 
Intelligence-III (WPPSI-III) (age 5), the Wechsler Abbreviated 
Scale of Intelligence (ages 7, 9, 11, and 13) for cognitive status, 
and the Wechsler Abbreviated Individual Achievement Test (ages 
7, 9, 11, and 13) for academic performance (42). We found no 
association between in  utero exposure to any ARV regimen or 
class and any cognitive or academic outcome. No individual ARV 
was significantly associated with lower cognitive or academic 
scores in unadjusted and adjusted analyses. Exposure to tenofovir 
was associated with a significantly higher WPPSI-III score (100.8 
vs. 96.1, p = 0.03).
Language emergence was evaluated at 1 year of age with the 
MacArthur–Bates Communicative Development Inventory (CDI) 
and at 2 years with the ages and stages questionnaire (ASQ). Late 
language emergence was defined as <10 percentile for any of four 
domains of the CDI and ≥1 SD below the age-specific normal 
value for the ASQ. Late language emergence was found in 26% of 
1-year-old HEU children and was independently associated with 
male sex, maternal CD4 <25%, viral load >400 copies/mL during 
late pregnancy, and caregiver IQ <85 (43). At 2 years of age, late 
language emergence was present in 23% and was independently 
associated with male sex and having a caregiver with limitations 
in activities. There was no significant association of late language 
emergence at either 1 or 2 years of age with maternal use of cARV, 
a PI, or an NNRTI. However, at 1 year, but not at 2 years, late 
language emergence was significantly and independently more 
likely among children whose mothers took atazanavir (OR 1.83, 
95% CI 1.10, 3.04, p =  0.02) or saquinavir (OR 2.72, 95% CI 
1.09, 6.91, p =  0.03) during the pregnancy. In addition, use of 
cARV by the newborn for prophylaxis, vs. zidovudine alone, was 
independently associated with late language emergence at 1, but 
not 2 years of age (OR 3.07, 95% CI 1.18, 7.97, p = 0.02). Among 
AMP participants, at a mean age of 12.0 years, we demonstrated 
that both HIV-infected and HEU children were at high risk for 
language impairment, although the risk was similar in the two 
groups (44).
COnCLUSiOn
The results of the SMARTT study to date are generally reassur-
ing, with little evidence for serious adverse events resulting from 
in  utero ARV exposure. However, there are several findings of 
concern that warrant further evaluation. The increased rate of 
premature delivery and selected birth defects with certain ARV 
exposures informs the choice of ARV for use during pregnancy. 
Atazanavir exposure is associated with lower language achieve-
ment at 1 year and a twofold higher risk of congenital anomalies 
(Figure 1). Atazanavir is known to increase unconjugated bili-
rubin levels in the blood, raising the concern that fetal bilirubin 
exposure resulting from transplacental passage of bilirubin could 
contribute to these findings. The association of tenofovir expo-
sure with decreased newborn bone mineral content and reduced 
growth at 1 year of age are predicted by prior studies and warrants 
further study to see if these findings persist as the children’s age. 
Likewise, it is important to determine if the subclinical cardiac 
abnormalities predict future premature heart disease. Finally, it 
is important to study new ARVs as pregnant women adopt their 
use.
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